Cancer Clinical Trial
Official title:
Meaning-Centered Grief Therapy for Parents Bereaved by Cancer: A Multisite Randomized Controlled Trial
The purpose of this study is to compare three types of support programs for parents who have lost a child. The study will see how these support programs affect participants' grief and depression symptoms. The three support programs are called Meaning-Centered Grief Therapy, Supportive Counseling, and Enhanced Usual Care.
Status | Recruiting |
Enrollment | 415 |
Est. completion date | May 31, 2026 |
Est. primary completion date | May 31, 2026 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - A biological, adoptive, step-parent or legal guardian from across the United States who lost a child diagnosed with cancer as indicated by self-report - Age 18 or older as indicated by self-report - Experienced the loss of a child diagnosed with cancer at least 6 months prior to enrollment as indicated by self-report - Elevated prolonged grief (PG) symptoms (PG-13-R scores of 30 or above) - Resides in a state in which a study clinical supervisor is licensed to permit telepsychology practice or otherwise able to comply with current telehealth regulations as indicated by self-report - English-speaking as per the language assessment items below and willing to receive the intervention in English. - What is the participant's preferred language? °(Specify Lang)___________________________ - How well does the participant speak English? - Very well (PARTICIPANT IS ELIGIBLE) - Well (PARTICIPANT is NOT ELIGIBLE) - Not well (PARTICIPANT is NOT ELIGIBLE) - Not at all (PARTICIPANT is NOT ELIGIBLE) Support Provider Inclusion Criteria: - Must be age 18 or over as indicated by self-report - Has been identified by the bereaved parent participant as a support or someone important to bereaved parent - Resides in a state in which a study clinical supervisor is licensed to permit telepsychology practice or otherwise able to comply with current telehealth regulations as indicated by self-report - English-speaking as per the language assessment items below and willing to receive the intervention in English - What is the participant's preferred language? °(Specify Lang)___________________________ - How well does the participant speak English? - Very well (PARTICIPANT IS ELIGIBLE) - Well (PARTICIPANT is NOT ELIGIBLE) - Not well (PARTICIPANT is NOT ELIGIBLE) - Not at all (PARTICIPANT is NOT ELIGIBLE) Family Participant Inclusion Criteria: - A biological, adoptive, step-parent or legal guardian from across the United States who lost a child diagnosed with cancer as indicated by self-report - Age 18 or older as indicated by self-report - Experienced the loss of a child diagnosed with cancer at least 6 months prior to enrollment as indicated by self-report - Resides in a state in which a study clinical supervisor is licensed to permit telepsychology practice or otherwise able to comply with current telehealth regulations as indicated by self-report - English-speaking as per the language assessment items below and willing to receive the intervention in English - What is the participant's preferred language? °(Specify Lang)___________________________ - How well does the participant speak English? - Very well (PARTICIPANT IS ELIGIBLE) - Well (PARTICIPANT is NOT ELIGIBLE) - Not well (PARTICIPANT is NOT ELIGIBLE) - Not at all (PARTICIPANT is NOT ELIGIBLE) Training Case Inclusion Criteria: - A biological, adoptive, step-parent, or legal guardian from across the United States as indicated by self-report - Age 18 or older as indicated by self-report - Experienced the loss of a child at least 6 months prior to enrollment as indicated by self-report - Score of 29 or below on the PG-13-R OR lost a child to a cause other than cancer OR child's additional guardian has consented as a Parent Participant and has not provided permission to share participation status - Resides in a state in which a study clinical supervisor is licensed to permit telepsychology practice or otherwise able to comply with current telehealth regulations as indicated by self-report - English-speaking as per the language assessment items below and willing to receive the intervention in English - What is the participant's preferred language? ° (Specify Lang)___________________________ - How well does the participant speak English? - Very well (PARTICIPANT IS ELIGIBLE) - Well (PARTICIPANT is NOT ELIGIBLE) - Not well (PARTICIPANT is NOT ELIGIBLE) - Not at all (PARTICIPANT is NOT ELIGIBLE) Training Case Support Provider Inclusion Criteria: - Must be age 18 or over as indicated by self-report - Has been identified by the bereaved parent training case participant as a support or someone important to bereaved parent - Resides in a state in which a study clinical supervisor is licensed to permit telepsychology practice or otherwise able to comply with current telehealth regulations as indicated by self-report - English-speaking as per the language assessment items below and willing to receive the intervention in English - What is the participant's preferred language? ° (Specify Lang)___________________________ - How well does the participant speak English? - Very well (PARTICIPANT IS ELIGIBLE) - Well (PARTICIPANT is NOT ELIGIBLE) - Not well (PARTICIPANT is NOT ELIGIBLE) - Not at all (PARTICIPANT is NOT ELIGIBLE) Participant Exclusion Criteria: - Significant psychiatric disturbance sufficient, in the investigator/study staff's judgment, to preclude completion of the assessment measures, interview or informed consent - Inability to access a functional device for videoconferencing and declines offer to use a study loaner device as indicated by self-report - Prisoners - Participants unable to consent Support Provider Exclusion Criteria: - Significant psychiatric disturbance sufficient, in the investigator/study staff's judgment, to preclude informed consent - Inability to access a computer with Internet as indicated by self-report - Prisoners - Participants unable to consent Family Participant Exclusion Criteria: - Significant psychiatric disturbance sufficient, in the investigator/study staff's judgment, to preclude informed consent - Inability to access a computer with Internet as indicated by self-report - Prisoners - Participants unable to consent Training Case Exclusion Criteria: - Significant psychiatric disturbance sufficient, in the investigator/study staff's judgment, to preclude completion of the assessment measures, interview or informed consent - Inability to access a functional device for videoconferencing and declines offer to use a study loaner device as indicated by self-report - Prisoners - Participants unable to consent Training Case Support Provider Exclusion Criteria - Significant psychiatric disturbance sufficient, in the investigator/study staff's judgment, to preclude informed consent - Inability to access a computer with Internet as indicated by self-report - Prisoners - Participants unable to consent |
Country | Name | City | State |
---|---|---|---|
United States | St Jude's Children's Hospital (Data collection only) | Memphis | Tennessee |
United States | University of Miami | Miami | Florida |
United States | Memorial Sloan Kettering Cancer Center | New York | New York |
United States | Children's Hospital of Philadelphia (Data Collection Only) | Philadelphia | Pennsylvania |
Lead Sponsor | Collaborator |
---|---|
University of Miami | National Institute of Nursing Research (NINR) |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Change in Prolonged Grief Disorder-13-R (PG-13-R) scores | The Prolonged Grief-13-Revised (PG-13-R) is a 13-item self-report scale evaluating the proposed symptoms of prolonged grief disorder. The PG-13-R assesses the severity of 10 grief-related symptoms using a 5-point Likert-type scale. Additional items evaluate the experience of a significant loss, symptom duration, and functional impairment. The PG-13-R yields a score between 10 and 50, where a higher score indicates that a person experiences higher levels of prolonged grief. | Baseline up to 10 months | |
Primary | Change in Center for Epidemiologic Studies Depression Scale - Revised (CESD-R) score | The Center for Epidemiologic Studies Depression Scale-Revised (CESD-R) is a 20-item self-report measure assessing the frequency of depressive symptoms in the past week on a 4-point scale. Total scores range from 0 to 60, with scores above 16 indicating possible clinically significant depression levels. | Baseline up to 10 months | |
Secondary | Change in PROMIS: Global Health Scale (PROMIS-GH) scores | The PROMIS-Global Health Scale (PROMIS-GH), is a National Institutes of Health-developed and well-validated self-report assessment that captures global mental health (i.e., quality of life, mental health, satisfaction with social activities, and emotional problems) and physical health (i.e., physical health, physical function, pain, and fatigue). PROMIS-GH consists of 10-items, with each utilizing a 7-day recall period. The initial 9-items make use of a 5-point scale, with 3 separate verbal anchors that ask patients to rate their health or abilities, indicate how often they are experiencing a phenomenon or how severe their symptomatic experience is. A final item asks patients to indicate their average pain on a 0-10 numeric rating scale (i.e., 0 = no pain, 10 = worst pain imaginable). The composite score is a sum of each item, and scores range from 10 to 50. | Baseline up to 10 months | |
Secondary | Change in State-Trait Anxiety Inventory - Short Form (STAI-SF) scores | The State-Trait Anxiety Inventory (STAI-SF) is a 10-item valid and reliable self-report measure of both state and trait anxiety. For both of these subscales, higher scores indicate higher levels of anxiety. Responses range from 1 (almost never) to 4 (almost always), with higher scores reflecting increased anxiety. | Baseline up to 10 months | |
Secondary | Change in Beck Hopelessness Scale - Short Form (BHS-SF) scores | The Beck Hopelessness Scale-Short Form (BHS-SF) is a 4-item true-false self-report measure of participants' degree of pessimism and hopelessness. Scores range from 0 to 12. A higher score indicates more experiences of pessimism or lack of hope. | Baseline up to 10 months | |
Secondary | Change in Presence of Regret Scale scores | The presence of regret and associated distress will be assessed by items used in the investigative team's prior research on regret. The measure asks respondents to rate level of distress associated with regret on a scale from 1-10 with higher scores indicating greater distress. | Baseline up to 10 months | |
Secondary | Change in Posttraumatic Growth Inventory - Short Form (PTGI-SF) scores | The Posttraumatic Growth Inventory-Short Form (PTGI-SF) is a 10-item self-report measure that assesses positive outcomes following stressful life events. Scores range from 0 to 50, and higher total scores reflect higher levels of posttraumatic growth. | Baseline up to 10 months | |
Secondary | Change in Continuing Bonds Scale (CBS) scores | The Continuing Bonds Scale (CBS) is an 11-item self-report measure that assesses the degree of continued connection with a deceased loved one on a 5-point scale. Scores range from 11 to 55, with higher scores reflecting a stronger continued bond. | Baseline up to 10 months | |
Secondary | Change in Prolonged Grief Disorder - Clinical Global Impressions Scale - Severity and Improvement Items (PGD-CGI) ratings | The Prolonged Grief Disorder-Clinical Global Impression Scale (PGD-CGI), adapted from trials examining Complicated Grief Treatment, will be used to assess global severity and symptom improvement. It is a two-item observer assessment that uses a seven-point scale for a global rating of illness severity and improvement. Scores range from 1 to 7, with lower scores indicating low severity of symptoms and improvement in functioning. | Baseline up to 10 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05346796 -
Survivorship Plan HEalth REcord (SPHERE) Implementation Trial
|
N/A | |
Recruiting |
NCT05094804 -
A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents
|
Phase 1/Phase 2 | |
Completed |
NCT04867850 -
Effect of Behavioral Nudges on Serious Illness Conversation Documentation
|
N/A | |
Enrolling by invitation |
NCT04086251 -
Remote Electronic Patient Monitoring in Oncology Patients
|
N/A | |
Completed |
NCT01285037 -
A Study of LY2801653 in Advanced Cancer
|
Phase 1 | |
Completed |
NCT00680992 -
Study of Denosumab in Subjects With Giant Cell Tumor of Bone
|
Phase 2 | |
Completed |
NCT00062842 -
Study of Irinotecan on a Weekly Schedule in Children
|
Phase 1 | |
Active, not recruiting |
NCT04548063 -
Consent Forms in Cancer Research: Examining the Effect of Length on Readability
|
N/A | |
Completed |
NCT04337203 -
Shared Healthcare Actions and Reflections Electronic Systems in Survivorship
|
N/A | |
Recruiting |
NCT04349293 -
Ex-vivo Evaluation of the Reactivity of the Immune Infiltrate of Cancers to Treatments With Monoclonal Antibodies Targeting the Immunomodulatory Pathways
|
N/A | |
Terminated |
NCT02866851 -
Feasibility Study of Monitoring by Web-application on Cytopenia Related to Chemotherapy
|
N/A | |
Active, not recruiting |
NCT05304988 -
Development and Validation of the EFT for Adolescents With Cancer
|
||
Completed |
NCT04448041 -
CRANE Feasibility Study: Nutritional Intervention for Patients Undergoing Cancer Surgery in Low- and Middle-Income Countries
|
||
Completed |
NCT00340522 -
Childhood Cancer and Plexiform Neurofibroma Tissue Microarray for Molecular Target Screening and Clinical Drug Development
|
||
Recruiting |
NCT04843891 -
Evaluation of PET Probe [64]Cu-Macrin in Cardiovascular Disease, Cancer and Sarcoidosis.
|
Phase 1 | |
Active, not recruiting |
NCT03844048 -
An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial
|
Phase 3 | |
Completed |
NCT03109041 -
Initial Feasibility Study to Treat Resectable Pancreatic Cancer With a Planar LDR Source
|
Phase 1 | |
Completed |
NCT03167372 -
Pilot Comparison of N-of-1 Trials of Light Therapy
|
N/A | |
Terminated |
NCT01441115 -
ECI301 and Radiation for Advanced or Metastatic Cancer
|
Phase 1 | |
Recruiting |
NCT06206785 -
Resting Energy Expenditure in Palliative Cancer Patients
|